Sponsor or institution
Clinical trials and research at Radiopharm Theranostics, Ltd
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Radiopharm Theranostics, Ltd that are recruiting, at sites in 2 countries (most in Australia (3), United States (1)). By phase: Phase 1/2 (2), Early Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Terbium‑161 RAD402 treatment for castration‑resistant prostate cancer | Phase 1/2 | Wollongong, New South Wales and 1 other locations | Recruiting | Dec 2, 2025 |
| 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors | Phase 1/2 | Dothan, Alabama and 4 other locations | Recruiting | Sep 24, 2025 |
| HER2 antibody therapy using Lutetium-177 for advanced solid tumors | Early Phase 1 | Kingswood, New South Wales and 4 other locations | Recruiting | Feb 13, 2025 |
| Using 177Lu-anti-PD-L1 for treating metastatic solid tumors | Early Phase 1 | Gosford, New South Wales and 5 other locations | Recruiting | Mar 12, 2024 |
All recruiting trials (4)
-
Terbium‑161 RAD402 treatment for castration‑resistant prostate cancer
This will test a radioactive antibody called 161Tb‑RAD402 to see if it is safe and can help men with castration‑resistant prostate cancer whose disease has progressed after prior treatments.
-
177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors
This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.
-
HER2 antibody therapy using Lutetium-177 for advanced solid tumors
This study is testing a new treatment using a special type of radiation for people with advanced solid tumors that are HER2 positive to see if it is safe and effective.
-
Using 177Lu-anti-PD-L1 for treating metastatic solid tumors
This study is testing a new treatment called 177Lu-RAD204 to see if it can safely help people with advanced solid tumors like lung cancer and melanoma.
Quick answers
How many clinical trials run by Radiopharm Theranostics, Ltd are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Australia (3 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.